Related Experiment Video

Updated: Apr 30, 2026

Dissecting Cell-Autonomous Function of Fragile X Mental Retardation Protein in an Auditory Circuit by In Ovo Electroporation
11:10

Dissecting Cell-Autonomous Function of Fragile X Mental Retardation Protein in an Auditory Circuit by In Ovo Electroporation

Published on: July 6, 2022

1.8K

Translating molecular advances in fragile X syndrome into therapy: a review

Randi J Hagerman1, Vincent Des-Portes, Fabrizio Gasparini

  • 1Department of Pediatrics and MIND Institute, School of Medicine, University of California, Davis.

The Journal of Clinical Psychiatry
|May 13, 2014
PubMed

Insights

Fragile X syndrome treatments are improving. Novel therapies targeting the genetic cause, not just symptoms, show promise in clinical research for this inherited neurological disorder.

Area of Science:

  • Neuroscience
  • Genetics
  • Pharmacology

Background:

  • Fragile X syndrome is an inherited neurological disorder with cognitive, behavioral, and neurologic symptoms.
  • Current treatments for Fragile X syndrome focus on symptom management and have limited efficacy.
  • A single genetic mutation underlies Fragile X syndrome, presenting a target for novel therapeutic strategies.

Purpose of the Study:

  • To review recent advances in understanding the molecular basis of Fragile X syndrome.
  • To summarize ongoing clinical research for novel pharmacologic treatments.
  • To highlight a shift towards targeting the molecular defect rather than symptoms.

Main Methods:

  • Review of current literature on Fragile X syndrome molecular basis.
  • Analysis of preclinical research in animal models for pharmacologic targets.
  • Summary of ongoing and recently completed clinical trials.

Main Results:

  • Significant progress in understanding the molecular mechanisms of Fragile X syndrome.
  • Development of novel pharmacologic agents targeting the underlying genetic defect.
  • Emerging clinical data on the efficacy and safety of these new treatments.

Conclusions:

  • Targeting the molecular basis of Fragile X syndrome offers a promising therapeutic avenue.
  • Novel pharmacologic treatments are advancing through clinical research pipelines.
  • Future treatments may offer improved outcomes for individuals with Fragile X syndrome.

More Related Videos

A Robust Polymerase Chain Reaction-based Assay for Quantifying Cytosine-guanine-guanine Trinucleotide Repeats in Fragile X Mental Retardation-1 Gene08:22

A Robust Polymerase Chain Reaction-based Assay for Quantifying Cytosine-guanine-guanine Trinucleotide Repeats in Fragile X Mental Retardation-1 Gene

Published on: September 16, 2019

7.1K
TMS: Using the Theta-Burst Protocol to Explore Mechanism of Plasticity in Individuals with Fragile X Syndrome and Autism10:58

TMS: Using the Theta-Burst Protocol to Explore Mechanism of Plasticity in Individuals with Fragile X Syndrome and Autism

Published on: December 28, 2010

16.4K

Related Concept Videos

Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
657
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Sex-linked Disorders01:43

Sex-linked Disorders

Like autosomes, sex chromosomes contain a variety of genes necessary for normal body function. When a mutation in one of these genes results in biological deficits, the disorder is considered sex-linked.
94.2K
X-linked Traits01:19

X-linked Traits

In most mammalian species, females have two X sex chromosomes and males have an X and Y. As a result, mutations on the X chromosome in females may be masked by the presence of a normal allele on the second X. In contrast, a mutation on the X chromosome in males more often causes observable biological defects, as there is no normal X to compensate. Trait variations arising from mutations on the X chromosome are called “X-linked”.
45.6K
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
449
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K